|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
over 3 years ago
Key Factors Attributing to a Successful Product Launchover 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaover 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixover 3 years ago
Co-creating New Innovationsover 3 years ago
The Potential Impact of the IRAover 3 years ago
Patient Hubs Continue Growthover 3 years ago
Social Media’s Complex Climbover 3 years ago
Industry Workforce Seeks Clarityover 3 years ago
Cybersecurity Threats & PharmaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
2
Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton
3
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million
4
Amazon Pharmacy Launches GLP-1 Delivery Service
5